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Tast year we initiated a new feature in which the editors
elected the articles that they judged to be the best of JACC
n the prior year. Only time will tell which of the many
xcellent studies we publish will have the greatest impact, or
n fact if that description will belong to a report we did not
ven accept. Nevertheless, we have tried to identify those
ntries that received the most enthusiastic critiques and
ere of the greatest interest to the editors.
NTERVENTIONAL CARDIOLOGY:
RUG-ELUTING STENTS (DES)
everal studies were published in JACC that show signifi-
ant benefits of DES compared to bare metal stents (BMS)
nd may potentially expand the (off-label) indications in
reas that have not yet been studied in randomized con-
rolled trials (RCTs).
Lemos et al. (1) performed primary percutaneous coro-
ary intervention (PCI) with sirolimus-eluting stents (SES)
n 186 consecutive patients with acute myocardial infarction
AMI) and compared them to 183 consecutive patients
reated with BMS in the preceding six months. No signif-
cant differences were noted in the incidence of death or
e-infarction. Target vessel revascularization (TVR) at 30
ays was similar, but a significant difference in favor of SES
as present at 300 days (9.4% vs. 17%, p  0.02), mainly
ue to fewer repeat PCIs. The rate of stent thrombosis was
% in the SES group and 1.6% in the BMS group. This
on-randomized registry is the first report to compare DES
ith BMS in AMI treated with PCI and shows a durable
enefit and no increased risk of stent thrombosis.
In the same registry, Hoye et al. (2) compared 56 cases of
e novo chronic total occlusions (CTO) with SES to 28
atients treated with BMS. At six-month follow-up, the
inary restenosis rate in the DES group was 9.1% with a
ean in-stent late lumen loss of only 0.13 mm. At one-year
ollow-up, the cumulative survival-free rate of major adverse
ardiac events (MACE) was higher in the SES group versus
he BMS group (96.4% vs. 82.8%, p  0.05). This small
bservational study was first to report that SES reduces
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gy, Oregon Health and Science University, Portland, Oregon.
Manuscript received November 15, 2004; accepted November 15, 2004.ACE in CTO compared to BMS, and needs confirma-
ion.
Schampaert et al. (3) evaluated the role of SES compared
o Bx-VELOCITY stents in an RCT of 100 patients with
mall coronary arteries (mean reference diameter 2.65 mm,
ean lesion length 14.5 mm). At eight-month angiographic
nd clinical follow-up, the use of SES was associated with
ower binary restenosis (2.3% vs. 52.3%, p  0.001), less
n-lesion late loss (0.12 vs. 1.02 mm, p  0.001), higher
n-stent minimal lumen diameter (MLD) (2.46 vs. 1.49
m, p  0.001), less clinically driven target lesion revascu-
arization (TLR) (4% vs. 18%, p  0.05), and improved
reedom from MACE at 270 days (96.0% vs. 81.7%, p 
.02). The dramatic impact on late loss in small vessels is
imilar to the findings in larger vessels and suggests that
ES should be the default stenting strategy in these lesions
4).
In an observational study, Iakovou et al. (5) reported the
rst study on the role of SES in 32 patients with aorto-ostial
esions compared to a variety of BMS. Angiographic
ollow-up showed less binary restenosis (11% vs. 51%, p 
.0001), late loss (0.21 vs. 2.06 mm, p 0.0001), TLR (6.3
s. 28%, p  0.001), and MACE (19% vs. 44%, p  0.02)
ith SES.
Orlic et al. (6) treated 155 consecutive patients with
ultivessel coronary artery disease (CAD) with a total of
73 SES (mean 3.1 lesions per patient) and showed a
ACE rate of 22.3% with 2.7% deaths and 3.6% myocar-
ial infarction (MI) and a TLR rate of 14.3% (but only 6.7%
f all lesions). Stent thrombosis occurred in 1.9% of pa-
ients, and total stent length was the best predictor of
ACE. This first report on multivessel stent placement
uggests that multivessel disease will continue to remain a
hallenge for effective treatment with DES.
Two studies reported either no effectiveness or worse
linical outcomes with other types of DES. In the Actino-
ycin Eluting Stent Improves Outcomes by Reducing
eointimal Hyperplasia (ACTION) study, Serruys et al. (7)
andomized 360 patients to either BMS or two doses of
ctinomycin-D. A revised follow-up angiographic protocol
howed that in-lesion late lumen loss was higher in both
ctinomycin-D groups compared to the BMS group as was
he six-month and one-year MACE, driven exclusively by
VR. In the Study to COmpare REstenosis Rate between
ueST and QuaDDS-QP2 (SCORE) trial (8) using the
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Highlights of the Year in JACC 2004 January 4, 2005:137–53aclitaxel derivative 7-hexanoyltaxol within an acrylate
olymer membrane mounted on a novel stent design,
ncidences of early and late stent thrombosis and MI were
ignificantly higher in the 7-hexanoyltaxol arm, leading to
remature cessation of enrollment. The investigators and
ponsors are to be commended for publishing these unflat-
ering studies that potentially shed light on the clinically
elevant differences in drugs, polymers, coatings, and deliv-
ry systems. They also reflect the sobering finding that,
lthough pre-clinical models of restenosis with DES may
redict angiographic findings, they often do not accurately
redict clinical events in patients, questioning the usefulness
f such models and how they are tested (9).
ERCUTANEOUS CORONARY INTERVENTION
rimary PCI in hospitals without on-site surgical
ackup. Wharton et al. (10) presented the Primary Angio-
lasty in Myocardial Infarction No cardiac Surgery On Site
PAMI No SOS) study, evaluating treatment of
hrombolytic-eligible AMI patients with primary PCI in
ospitals having cardiac catheterization laboratories but no
urgical backup. They compared this group to a cohort
erived from the Air Primary Angioplasty in Myocardial
nfarction (AIR PAMI) study who underwent transfer to a
rimary PCI center without thrombolytics. The combined
rimary end point of 30-day mortality, re-infarction, and
isabling stroke occurred in 5.0% of on-site PCI patients
nd 8.5% of transfer patients (p  0.27). Unadjusted
ne-year mortality was similar with on-site PCI compared
o transfer after adjustment for differences in baseline
ariables. Transferred patients had a longer mean time to
reatment and diminished Thrombolysis In Myocardial
nfarction (TIMI) flow grade 3. Although observational and
on-randomized, this study has significant public health
mplications as it suggests that primary PCI in patients with
igh-risk AMI at hospitals with off-site cardiac surgical
ackup is as safe and effective, and significantly faster than
ransfer to a surgical facility for PCI. As pointed out in an
ditorial (11), primary PCI should be the favored approach
or ST-segment elevation AMI and it should no longer be
cceptable to give thrombolytics when mechanical interven-
ion is available.
se of PCI in diabetics. Patients with diabetes continue to
ave poorer outcomes compared to nondiabetic patients
ven in the current interventional cardiology era. Corpus et
l. (12) evaluated the role of optimal glycemic control
HgA1c 7%) following PCI with BMS in 179 diabetics
ompared to 60 nondiabetics in a single-center retrospective
tudy. At 12 months, diabetics with optimal glycemic
ontrol had a similar rate of TVR compared to nondiabetics.
owever, diabetics with HgA1c 7% had a significantly
igher rate of TVR than those with HgA1c 7% (34% vs.
5%, p  0.02). Optimal glycemic control was also associ-
ted with a lower rate of cardiac rehospitalization and
ecurrent angina. This study provides impetus for additional GCTs to study the effects of optimal glycemic control
ollowing PCI (13).
ercutaneous treatment of patent foramen ovale (PFO)
n cryptogenic stroke. The RCTs evaluating the safety and
ffectiveness of percutaneous PFO closure devices for the
reatment of cryptogenic stroke have not yet been carried
ut. In a nonrandomized study, Windecker et al. (14)
valuated the risk of stroke recurrence in 308 patients with
ryptogenic stroke and PFO, who were treated either
edically (158 patients) or underwent percutaneous PFO
losure (150 patients) between 1994 and 2000. At four years
f follow-up, PFO closure resulted in a strong trend toward
isk reduction of death, stroke, or transient ischemic attack
ombined (8.5% vs. 24.3%, p  0.05). Approximately 50%
f the medically treated patients were on warfarin and the
emainder were on aspirin. This study suggests that dra-
atic benefits in reducing recurrent cryptogenic stroke
bove and beyond medical therapy may be difficult. Care-
ully selected inclusion and exclusion criteria and appropri-
te medical therapy will be crucial in the design of future
tudies to assess the efficacy of this promising treatment
15).
ost-effectiveness. The issue of cost-effectiveness is be-
oming more important as it becomes increasingly harder to
how benefits in mortality with newer therapies. Two
tudies published in JACC showed the cost-effectiveness of
istal protection devices and bivalirudin. Cohen et al. (16)
erformed an economic analysis of the Saphenous vein graft
ngioplasty Free of Emboli Randomized (SAFER) trial
valuating the GuardWire balloon occlusion device, which
educes MACE in patients undergoing PCI of stenosed
aphenous vein bypass grafts. Use of the GuardWire device
ncreased initial procedural costs by $1,600. However, the
ean length of hospital stay was reduced by 0.4 days, owing
o a reduction in ischemic complications, decreasing
ollow-up hospital costs, and leading to an overall net cost of
582 per patient. Overall, the incremental cost-effectiveness
atio for distal protection was $3,718 per year of life saved,
ess than the accepted yardstick of $40,000.
The Randomized Evaluation of PCI Linking Angiomax
o Reduced Clinical Events (REPLACE-2) trial showed
hat patients undergoing non-emergent PCI with bivaliru-
in plus provisional glycoprotein (GP) IIb/IIIa had equal
schemic outcomes but lower rates of major and minor
leeding compared to patients treated with heparin plus
outine GP IIb/IIIa. Bivalirudin and provisional GP IIb/
IIa inhibition resulted in an actual cost savings of $375 to
400 per patient, which was primarily due to the lower costs
f bivalirudin compared to other GP IIb/IIIa (16).
EART FAILURE (HF)/CARDIAC TRANSPLANTATION
se of phosphodiesterase-5 (PDE5) inhibition in HF
atients. Recent evidence suggests that use of a PDE5
nhibitor may benefit patients with pulmonary hypertension.
uazzi et al. (17) assessed the acute effects of 50 mg of
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January 4, 2005:137–53 Highlights of the Year in JACC 2004ildenafil or placebo on cardiac function, pulmonary hemo-
ynamics, and exercise performance in 16 HF patients and
normal subjects. Although sildenafil did not affect ejection
raction (EF) or pulmonary artery wedge pressure in the HF
atients, it significantly lowered pulmonary artery pressure
20%) and increased carbon monoxide diffusion capacity
DLCO). Sildenafil also increased brachial artery reactivity,
nd during exercise it improved peak oxygen consumption
VO2), aerobic efficiency (VO2/W), and ventilatory efficiency
VE/VCO2). Although these findings suggest that PDE5
nhibition may be useful for the treatment of chronic HF,
urther long-term studies are needed to help define this
ossibility.
ssociation between loop diuretics and cardiac fibro-
is. Recognition of the fact that collagen turnover in the
eart is a dynamic and highly regulated process has stimu-
ated interest in defining factors that promote fibrosis as well
s new therapeutic approaches to treat this problem. Lopez
t al. (18) hypothesized significant differences may exist
etween loop diuretics in collagen turnover and cardiac
brosis. The investigators randomized patients with symp-
omatic HF to either torsemide 10 to 20 mg/day (n  19)
r furosemide 20 to 40 mg/day (n  17) on top of existing
herapy. They found that torsemide but not furosemide
ignificantly reduced cardiac fibrosis in biopsy specimens
nd indices of collagen synthesis (without change in colla-
en degradation). These results raise the interesting possi-
ility that loop diuretics might have heterogeneous effects
n cardiac fibrosis in HF patients.
A possible explanation for the antifibrotic effects of
orsemide was presented by Tsutamoto et al. (19) who
etermined transcardiac extraction of aldosterone in HF
atients treated with loop diuretics. In this study, 60
atients were randomly assigned to receive either furo-
emide (n 30) or torsemide (n 30) for one month. Over
his period there were no differences in measures of cardiac
unction, clinical status, or plasma aldosterone levels. How-
ver, the investigators found that there was aldosterone
ptake in the heart in the patients randomized to furo-
emide but not in the group that received torsemide.
ecause aldosterone is believed to play a critical role in
romoting remodeling of the heart and, in particular,
ncreased deposition of fibrous tissue, results of this study
upport the findings of Lopez et al. (18) noted in the
receding text, which demonstrate antifibrotic effects of
orsemide.
alue of in-hospital initiation of angiotensin-converting
nzyme inhibitors (ACEIs) and beta-blockers. Despite
bundant evidence that ACEIs and beta-blockers produce
ubstantial improvements in the clinical course of HF,
urveys consistently indicate that these therapies are unde-
utilized. Two JACC articles in the past year indicate that
his important deficiency can be improved. Butler et al. (20)
valuated long-term outpatient ACEI use following an
ndex HF hospitalization. They found that 67% of patients
ere discharged on ACEIs but that nearly one-third of ahem failed to refill their prescription by six months. In
ontrast, of patients with no discharge order for ACEIs,
nly 12.7% had filled such a prescription by 30 days.
nterestingly, neither demographic characteristics, EF, or
he presence of hypertension or diabetes was related to the
lling of an ACEI prescription. The investigators con-
luded that for HF patients who are discharged on ACEIs,
here is a significant decline in use after discharge. Patients
ot discharged on ACEIs are unlikely to be started as
utpatients.
A possible solution to the issues raised by Butler et al.
20) comes from Gattis et al. (21) who report the results of
he Initiation Management Predischarge: Process for As-
essment of Carvedilol Therapy in Heart Failure
IMPACT-HF) study. This study prospectively evaluated
hether pre-discharge carvedilol initiation in stabilized
atients hospitalized for HF increased the number of
atients treated with beta-blockade at 60 days without
ncreasing side effects or length of hospital stay. For the
rimary end point of the study, 91.2% patients randomized
o pre-discharge carvedilol initiation were treated with a
eta-blocker at 60 days post-discharge as compared to
3.4% of patients randomized to initiation post-discharge.
oreover, pre-discharge initiation was not associated with
ncreased serious adverse events or increased hospital stay.
he researchers concluded that the excellent uptake of
eta-blocker therapy seen in this study can be attributed to
xtensive pre-discharge treatment planning, and that this is
urther improved by in-hospital initiation of therapy.
An issue of practical importance is the order in which the
eurohormonal blocking agent drugs should be started.
raditionally, an ACEI is started first based in part on the
rder in which the agents were approved for the treatment
f HF. Sliwa et al. (22) investigated whether this practice is
eally optimal. In a single-center randomized trial, these
nvestigators compared the therapy with carvedilol either
efore (n  38) or after (n  40) perindopril in newly
iagnosed HF patients with idiopathic dilated cardiomyop-
thy. At 12 months, the group receiving carvedilol as initial
herapy achieved a higher tolerable dose of carvedilol, a
ower dose of furosemide, and better improvements in
ymptoms, left ventricular (LV) EF, and plasma N-terminal
ro-brain natriuretic peptide (BNP) concentrations. These
esults argue that initiation of therapy with a beta-blocker
rior to an ACEI may be preferable for HF.
ssociation between insulin resistance and cardiac dys-
unction. Although insulin resistance has been shown to be
risk factor for ischemic cardiomyopathy, its role in the
athogenesis of idiopathic dilated cardiomyopathy (IDCM)
as been uncertain. Witteles et al. (23) studied glucose
etabolism in 43 consecutive patients with IDCM who
ere not diabetic and who did not have significant comor-
id conditions. Compared to matched controls, plasma
lucose responses were significantly higher during an oral
lucose tolerance test in IDCM patients and this was
ssociated with significantly higher plasma insulin concen-
t
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Highlights of the Year in JACC 2004 January 4, 2005:137–53rations. These findings raise the possibility of a causal link
etween the two conditions. Although further verification
f this association is needed, these findings could be of
mportance given the rising incidence of type II diabetes in
he population.
ole of adrenergic genotype in modulating cardiac sym-
athetic drive and heart rate in HF. Overactivation of the
ympathetic nervous system occurs in HF and plays an
mportant pathophysiologic role in the progression of this
ondition. Functionally relevant polymorphisms of the
lpha-2, beta-1, and beta-2 adrenoceptors have been iden-
ified. Kaye et al. (24) determined the beta-1, beta-2, and
lpha-2C adrenoceptor genotype in 60 patients with severe
ongestive heart failure (CHF) in conjunction with mea-
urement of cardiac and systemic sympathetic activity using
he radiotracer norepinephrine spillover method. They
emonstrated a strong relationship between heart rate and
he level of cardiac adrenergic drive. Moreover, for a given
evel of cardiac adrenergic drive, heart rate was substantially
reater in patients with the Arg/Arg16 beta-2 adrenoceptor
olymorphism but not for polymorphisms of the beta-1
drenoceptor. The genotype of the alpha-2C and beta-2
drenoceptors, which are both located pre-junctionally, was
ot, however, related to the rate of norepinephrine release
rom cardiac sympathetic nerves. These findings provide the
nitial evidence that beta-2 adrenoceptor polymorphisms
ignificantly influence the relationship between heart rate
nd cardiac adrenergic drive in HF patients. These findings
ave potential clinical relevance in that they may help
xplain the greater (or lesser) sensitivity of certain individ-
als to the development of HF and could indicate which
atients are more likely to derive benefit from adrenergic-
locking agents.
An indication that genotyping of HF patients for certain
olymorphisms might be important in helping to determine
herapy was contained in a report from McNamara et al.
25) who evaluated the interaction of ACEI therapy with
he effect of the ACE D/I polymorphism on HF survival.
he ACE deletion allele (ACE-D) is associated with
ncreased ACE activity and presumably higher levels of
ngiotensin II. In this prospective study, 479 subjects with
ystolic dysfunction were divided based on ACE inhibitor
herapy into low dose (50% of target dose, n  227),
tandard dose (50%, n  201), or those receiving angio-
ensin receptor antagonists (n  51). The investigators
ound that the ACE-D allele was associated with an
ncreased risk of events but that this effect was primarily in
he low-dose group. Furthermore, the impact of beta-
lockers and a high dose of ACEIs was greatest in subjects
ith the ACE DD genotype and was less apparent with the
I and ID genotypes. Thus, evidence that higher doses of
CEIs diminished the impact of the ACE D allele, and
hat the benefits of beta-blockers and high-dose ACEIs
ppeared maximal for DD patients, suggests that determin-
ng ACE genotype may help target therapy for patients withF in the future. relection of patients for cardiac transplantation in the
urrent era of HF therapy. Recent advances in therapy
ave greatly improved the clinical course of HF patients. To
etermine how these changes might affect the selection of
atients for cardiac transplantation Butler et al. (26) evalu-
ted the relationship between survival, peak exercise VO2,
nd Heart Failure Survival Score (HFSS) in the current era
f HF therapy compared with survival post-cardiac trans-
lantation in 320 patients followed from 1994 to 1997
past-era) and 187 patients followed from 1999 to 2001
current-era). Outcomes were compared between these two
roups and patients who underwent cardiac transplantation
etween 1993 and 2000. The investigators found that
urvival with medical therapy in the past era was 78% at one
ear and 67% at two years compared with 88% and 79%,
espectively, in the current era (both p  0.01) and that
urvival was improved in the current era regardless of peak
O2. Of interest was the finding that with current therapy
5% of patients with peak VO2 10 to 14 ml/min/kg had a
ow-risk HFSS and that this group exhibited an 88%
ne-year event-free survival which was similar to results
eported with cardiac transplantation. These results suggest
hat improved survival for HF patients in the current era
hould lead to re-evaluation of the criteria used for listing
or cardiac transplantation.
CHOCARDIOGRAPHY
lthough echocardiography is now well incorporated into
aily practice, new approaches including three-dimensional
chocardiography, contrast echocardiography, and tissue
oppler imaging are emerging as important clinical appli-
ations.
tress echocardiography. Although stress echocardiogra-
hy is well established in the assessment of CAD, several
eports published in 2004 expanded the role for this tech-
ique in complex clinical settings. Bergeron et al. (27)
tudied the role of exercise echocardiogram (ExE) in pre-
icting the outcome of patients referred for testing due to
yspnea. They compared the results of ExE in 443 patients
ith unexplained dyspnea to that of 2,033 patients with
hest pain and 557 patients with both symptoms. Patients
eferred for dyspnea alone were older and had more cardio-
ascular abnormalities than the other groups. Ischemia on
xE was found in 42% of patients with dyspnea, 19% of
atients with chest pain, and 58% with both symptoms.
uring 3.1 years of follow-up, cardiac death and nonfatal
I occurred more often in patients with dyspnea. Thus,
his study demonstrated that patients referred for ExE for
nexplained dyspnea have a high likelihood of myocardial
schemia and an increased incidence of cardiac events as
ompared to other patient cohorts, establishing an impor-
ant role for ExE in this clinical setting.
In another study, Hillis et al. (28) examined the response
f akinetic segments to exercise testing with echocardiog-
aphy. Although the appearance of a new contractile abnor-
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January 4, 2005:137–53 Highlights of the Year in JACC 2004ality with exercise is clear evidence of myocardial isch-
mia, the response of akinetic segments was less well
efined. Of 1,005 consecutive patients, 10% developed
yskinesis during exercise, and these more often manifested
rior MI, a blunted blood pressure response, and electro-
ardiographic (ECG) ischemia than those in whom akinesis
as unchanged. However, all-cause mortality and major
ardiac events were similar over a median of 2.7 years. Thus,
lthough patients in whom akinetic segments become dys-
inetic manifest evidence of more severe ischemic heart
isease, their overall prognosis is not adversely affected in
he near term.
Reis et al. (29) evaluated the role of dobutamine stress
chocardiography (DSE) in risk stratification of patients
ith rheumatic mitral stenosis. In 53 patients followed for a
ean of 5 years, mean mitral valve gradient and peak
obutamine infusion was the best predictor of clinical
vents, and a mean gradient of 18 mm Hg at peak exhibited
sensitivity of 90% and specificity of 87% in predicting
ubsequent clinical events. Thus, DSE may have a role in
dentifying patients with mitral stenosis who are candidates
or interventional therapy.
hree-dimensional echocardiography (3DE). Although
he clinical applications of real-time 3DE imaging are not
ully defined, the most immediate impact was predicted to
e enhanced quantitation. Kuhl et al. (30) validated a
ombination of 3DE and a semi-automated border detec-
ion algorithm in quantitating LV volumes and function.
he results of manual tracing and the border detection
lgorithm were compared to cardiac magnetic resonance
maging (CMR). Both approaches to 3DE data correlated
ell with CMR (r  0.98), with a small standard error of
he estimate. In another study, Jenkins et al. (31) examined
he ability of 3DE to reduce the variability of LV size and
unction measurements obtained by ultrasound. Fifty pa-
ients underwent separate two-dimensional echocardiogram
2DE) and 3DE performed by different sonographers
ithin 1 h, and results were compared to CMR. Measures
f LV function and EF by both 2DE and 3DE correlated
ell with CMR, although echocardiography often mani-
ested a systematic underestimation. Importantly, the vari-
tion in measurements exhibited by 2DE was substantially
educed by the three-dimensional technique. Thus, these
tudies demonstrated that real-time 3DE can reduce the
nter-test variation in the assessment of LV size and
unction and, therefore, yield a more robust method for
erial observation and assessing interventions.
issue velocity imaging. Although the ability to measure
ntrinsic myocardial velocity by Doppler tissue imaging
DTI) has been available for some time, new applications
nd the derivation of strain rate have increased the clinical
ole, especially the assessment of ventricular asynchrony.
hus, Bader et al. (32) evaluated DTI abnormalities as
ndependent predictors of cardiac events in HF patients. In
04 patients with LV EF 45%, they measured interven-
ricular and LV intraventricular regional electromechanical eelays and catalogued the incidence of hospitalization for
ecompensation. They found that intra-LV but not inter-
entricular asynchrony predicted cardiac events. Impor-
antly, a weak correlation existed between QRS width
nd asynchrony by DTI, and 56% of patients with a QRS
idth of 120 ms manifested intra-LV asynchrony.
hus, the detection of intra-LV asynchrony by DTI mea-
urements can identify HF patients at increased risk of
ecompensation.
A number of studies utilized DTI to identify HF patients
ho will benefit from cardiac resynchronization therapy
CRT). Bax et al. (33) reported on 85 end-stage HF
atients with left bundle branch block (LBBB) and QRS
120 ms in whom clinical class, exertional capacity, and LV
ize and function were determined at 6 months and death
nd rehospitalization were ascertained at 1 year. The
eceiver-operating characteristic (ROC) curve analysis dem-
nstrated that optimal separation of the 74% of responders
rom 26% of nonresponders occurred with a cutoff value of
5 ms of dyssynchrony manifested by a delay between the
ime to peak systolic velocity of the septum and lateral wall.
In another study, Bordachar et al. (34) evaluated the
elationship between cardiac output and ventricular dyssyn-
hrony parameters in patients undergoing CRT. They
ound that cardiac output correlated optimally with intra-
entricular delays in the time to onset of systolic velocity or
ime to peak systolic velocity. In patients in whom optimal
acing minimized dyssynchrony, reverse LV remodeling
as observed at three months. Thus, these studies demon-
trate that tissue velocity imaging can play an important role
n identifying patients likely to respond to CRT, and in
uiding the optimal pacing strategy to be applied. The
echanism by which CRT reduces mitral regurgitation
MR) was evaluated by Doppler velocity imaging by
anzaki et al. (35). In 26 patients with at least mild MR
ho underwent CRT, regurgitant volume decreased from
8 to 22 ml. This reduction was significantly correlated with
shortening in the time delay between the insertion sites of
he papillary muscles (r  0.77). Thus, CRT produced an
mmediate reduction in MR that correlated with the timing
f mechanical activation of the papillary muscle insertion
ites, providing a feasible mechanism for this effect by CRT.
In another report, measurements of positive pre-ejection
elocity derived from tissue velocity imaging were applied to
redict a recovery of LV function after recanalization of an
ccluded coronary artery by Penicka et al. (36). They
tudied 43 patients with MIs due to an occluded coronary
rtery in whom revascularization was achieved. They ob-
erved that a positive pre-ejection velocity exhibited a
ensitivity and specificity of 91% and 71%, respectively, in
dentifying dysfunctional segments that improved at three
onths. Thus, tissue velocity imaging provides criteria with
hich to predict the recovery of function in dyssynergic
egments following revascularization.
Finally, Hillis et al. (37) assessed whether the ratio ofarly diastolic blood flow (E) to mitral annular (e=) by DTI,
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Highlights of the Year in JACC 2004 January 4, 2005:137–53hich has been shown to predict LV filling pressures can
redict survival following AMI. The current study demon-
trated that patients in whom the E/e= was 15 manifested
4.8 risk ratio for all cause mortality, thereby providing
ncremental prognostic information to other echocardio-
raphic measurements.
ontrast echocardiography. Several studies reported last
ear provided evidence of the increasing usefulness of
ontrast echocardiography in clinical practice. Malm et al.
38) applied contrast echocardiography in an attempt to
ncrease the accuracy and reproducibility of LV size and
unction measurements. They compared standard and
ontrast-enhanced 2DE against CMR in 110 consecutive
atients. They found that limits of agreement between
chocardiography and CMR narrowed significantly with
ontrast from 8.3% to 4.1% for LV EF. Importantly, the
ariability in the readings of two observers for LV EF was
educed considerably from standard echocardiography
14%) to contrast-enhanced echocardiography (7%), and
ntraobserver variability for LV EF decreased from 7.8% to
.4%. Thus, this study demonstrated that the use of LV
pacification by contrast echocardiography can yield mea-
urements of LV size and function that are comparable in
eproducibility to CMR. In another study, Kirkpatrick et al.
39) applied contrast echocardiography to differentiate car-
iac masses due to thrombi from those due to tumors. They
xploited the greater vascularity of tumors and demon-
trated an increased signal intensity of tumors following
ontrast injection that was not visualized in thrombi.
Although most myocardial contrast echocardiography
MCE) protocols that identify CAD have utilized vasodi-
ators, the standard agent for stress echocardiography is
obutamine. Elhendy et al. (40) injected boluses of ultra-
onic contrast intravenously at immediate and peak stress
uring DSE in 170 patients undergoing coronary angiog-
aphy. Overall, the diagnostic accuracy was higher for MCE
han wall motion abnormalities on unenhanced echocardi-
graphy (81% vs. 71%; p  0.01) and the sensitivity was
reater for detecting abnormalities in multiple vascular
egions. Thus, the bolus injection of ultrasonic contrast
uring DSE can provide enhanced diagnostic accuracy in
ssessing CAD. The need for enhanced quantitation of
CE was examined by Yano et al. (41). To address the
eterogeneity of intensity among individual myocardial
egments during MCE, these investigators derived mea-
urements from both the subendocardium and adjacent LV
avity for individual segments. The calibrated intensity
btained by subtracting cavity from myocardial intensity of
ach segment reduced inter-segmental differences from 16
o 6 dB. As pointed out in an accompanying editorial by
indner and Sklenar (42), the development of semi-
utomated quantification programs is driven by the need to
nhance the performance of the human interpreter, and
pproaches such as those of Yano et al. (41) will be of value
n this regard. wransesophageal and intravascular echocardiography. The
reatment of prosthetic valve thrombosis continues to
resent a clinical challenge. Tong et al. (43) reported the
valuation of transesophageal echocardiography (TEE)
o provide risk assessment of thrombolysis of prosthetic
alve thrombosis from the international Prosthetic Valve
hrombolysis Role of Transesophageal Echocardiography
PRO-TEE) registry. Of 107 patients from 14 international
enters who presented with suspected prosthetic valve
hrombosis and underwent TEE followed by thrombolysis,
xtension of thrombosis beyond the valve ring and the area
f the thrombus proved to be predictors of complications.
owever, only thrombosis area was an independent risk
tratifier. Thus, findings from TEE can be important in
redicting complications from thrombolytic therapy of
rosthetic valves. Hamilton et al. (44) presented data on the
bility to image atheromas by combined administration of
argeted echogenic immunoliposomes and intravascular ul-
rasound. In atherosclerosis produced in mini swines, these
nvestigators were able to observe enhancement following
he injection of anti-adhesion molecules, anti-tissue factor,
nd anti-fibrinogen conjugated echogenic immunolipo-
omes. These data point to a potentially important role for
chocardiography in the molecular imaging of atheroscle-
otic plaques.
AD RISK ASSESSMENT
ekker et al. (56) studied the predictive value of heart rate
orrected QT interval (QTc) for incident coronary heart
isease (CHD) and cardiovascular disease (CVD) mortality
n 14,548 black and white men and women age 45 to 64
ears. Their results indicated that the age-, gender-, and
ace-adjusted hazard ratios for CVD mortality and CHD in
ubjects with the longest 10% relative to the other 90% of
he gender-specific QTc distribution were 5.13 and 2.14,
espectively. They noted that the increased risk was partly,
ut not completely, attributable to other risk factors or the
resence of chronic disease. The association was stronger in
lack than in white subjects. In an accompanying editorial
omment, Okin (57) noted that although additional study is
equired to clarify the meaning and mechanisms of a
rolonged QTc, the Dekker et al. (56) findings strongly
upport the value of careful, quantitative electrocardiogra-
hy in the application of QTc prolongation for risk strati-
cation in the general population.
Sachdev et al. (58) considered the long-term prognostic
mportance of comorbid illness by examining a cohort of
,471 patients with CAD who underwent cardiac catheter-
zation between 1985 and 1989 and were followed through
000 in the Duke Databank for Cardiovascular Diseases. A
ew CAD-specific index was created by assigning weights
o individual diseases according to their prognostic signifi-
ance using Cox proportional hazard models. The new
ndex was compared with the widely used Charlson index,
hich is not specific to CAD, and was found to have a
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opulation. In an accompanying editorial comment, Hlatky
59) noted the new CAD-specific index has considerable
ace validity, and that “the CAD-specific index is likely to
e a very useful measure in studies of mortality among
atients with coronary disease.”
Scuteri et al. (60) evaluated whether the clustering of
ultiple components of the metabolic syndrome has a
reater impact on vascular thickness and stiffness than the
ndividual components. They studied 471 participants from
he Baltimore Longitudinal Study on Aging without clinical
VD. They concluded that the components of the meta-
olic syndrome interact to synergistically impact the vascular
arameters. In an accompanying editorial comment,
omanski and Proschan (61) noted that the metabolic
yndrome is a series of synergistically interacting risk factors
or CVD, many or all of which may share a common
tiology. They also suggested that delineation of the etiol-
gy of the syndrome, and its heterogeneity, will be useful in
efining prevention and treatment strategies.
UCLEAR CARDIOLOGY, CARDIAC CT, AND CMR
ingle-photon emission computed tomography (SPECT).
or purposes of diagnosis, Bayesian analysis dictates that
yocardial perfusion SPECT (MPS) is best applied in
atients with an intermediate likelihood of having CAD; for
urposes of risk assessment in chronic CAD, the technique
s commonly employed in patients with known CAD. Two
tudies published in JACC in 2004 supported the application
f this method to patients with a high likelihood of CAD.
achamovitch et al. (62) reported the prognostic and cost
mplications of stress MPS in 1,270 patients referred for
xercise or adenosine MPS without known CAD but with
high pretest likelihood (0.85) of CAD based on age,
ender, symptoms, and CAD risk factors. Normal MPS was
ound in 47% of the patients studied, and in those treated
ithout early revascularization, it was associated with low
isk of cardiac death and hard events (0.6% and 1.3%/year,
espectively). With increasing extent and severity of MPS
efects, the risk of events increased significantly. Compared
ith strategies of initial referral to exercise testing, initial
eferral to MPS was a more cost-effective strategy in these
atients. Of additional interest, this study documented for
he first time that the current pattern of clinical use of MPS
as created a referral bias to revascularization of most
schemic patients, which results in underestimation of the
rognostic value of MPS when only non-revascularized
atients are considered in studies.
Poornima et al. (63) reported similar findings in a related
atient group but defined differently—by applying a rule-
ased clinical score to define patient risk. They studied the
alue of MPS in 1,461 symptomatic patients with a low
uke Treadmill Score (DTS) who were further stratified
sing a validated clinical score (CS) in which points were
ssigned for male gender, history of MI, diabetes, insulin gse, and age (each decade over 40 years). In patients with
ow clinical risk (CS 5), the seven-year cardiac survival
as 99%, even when the MPS was abnormal. A high risk
S (5), was found in 303 patients (21%). In these
atients, a group analogous to those with a high likelihood
f CAD in the study by Hachamovitch et al. (62), the
nnual cardiac mortality was not low (1%), and MPS had
ndependent prognostic value. The results of these two
tudies show that a stress MPS strategy is a reasonable
lternative to direct referral to catheterization in patients
ith high clinical risk, defined either by the likelihood of
AD or a rule-based scoring approach.
oronary calcium. Assessment of coronary artery calcium
CAC) using electron beam or multidetector spiral com-
uted tomography (MSCT) has become commonly em-
loyed as a noninvasive method for assessment of coronary
therosclerosis, with impact on patient prognosis and man-
gement. The relationship between CAC and ischemia by
oninvasive testing is less well understood. Berman et al.
64) assessed the 1,195 consecutive patients with no history
f CAD who had CAC and stress MPS. Among patients
ith a calcium score 100, MPS ischemia was rare,
ccurring in 2% of such patients. As the CAC score
ncreased, the frequency of myocardial ischemia on MPS
ncreased progressively, becoming intermediate with CAC
cores 400. The likelihood of myocardial ischemia by
PS was more tightly related to the absolute CAC score
han age- and gender-stratified CAC percentile score.
mportantly, in the 1,119 patients with normal MPS, a large
roportion had high enough CAC scores that there would
e consensus that aggressive medical management is war-
anted: 56% had CCS 100 and 31% had CCS 400.
Thus, low CAC scores appear to obviate the need for
ubsequent noninvasive testing. Patients with normal MPS,
owever, frequently have extensive atherosclerosis by CAC
riteria, implying a potential role for applying CAC screen-
ng after a normal MPS study. Further assessment of
therosclerotic burden by CAC testing in patients with
ormal MPS may be useful in assessment of the need for
ggressive medical therapy and dietary and exercise mea-
ures to prevent coronary events.
ultislice CT. Recent technical advances in MSCT scan-
ers have begun to make the noninvasive CT coronary
ngiogram a clinical reality. Several clinical manuscripts in
ACC in 2004 provided new evidence regarding the accuracy
f CT coronary angiography with these recent generation
T scanners compared with catheter-based coronary an-
iography (65–68). Mollet et al. (65) prospectively evalu-
ted the diagnostic performance of a recent generation
SCT scanner—a 16-slice CT scanner with rotation time
f 420 ms—in 128 patients with chest pain in sinus rhythm
cheduled for conventional coronary angiography, employ-
ng a 100 ml intravenous injection of iodinated contrast
ver 25 s. The diagnostic performance of MSCT coronary
ngiography was compared with quantitative coronary an-
iography (QCA). The sensitivity and specificity for detec-
t
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Highlights of the Year in JACC 2004 January 4, 2005:137–53ion of individual coronary stenoses (50%) was 92% and
5%, respectively. On a patient basis, all patients with and
6% of patients without significant lesions on QCA were
orrectly classified by MSCT, as were all patients with
ignificant left main stenosis or total occlusions.
Scanners have recently become available providing rota-
ion times of 350 ms (implying half-rotation true tomo-
raphic imaging in about 175 ms) and broad coverage so
hat computed tomographic angiography can be completed
n about 10 s or less. While previous generation scanners
ould only be used with high success rates in patients with
eart rates 65 beats/min, the fast rotation times will allow
omewhat higher heart rates. These new CT scanners
rovide true three-dimensional data with voxel dimensions
s low as 0.4 mm. The broader spatial coverage of these
canners will result it scan times as short as 5 to 10 heart
eats, and will require less intravenous contrast. Despite
hese highly encouraging results and developments, the
pproach will require relatively low heart rates, regular
hythm, and careful attention to quality control. Addition-
lly, assessment of the coronary lumen in the presence of a
oronary stent may still prove problematic, and even the
ighest resolution scanners available are unable to detect
oronary stenosis areas with dense calcification.
ssessment of vascular reactivity. Although identification
f the anatomic severity of coronary stenosis remains of
reat clinical importance, there has been burgeoning interest
n the dynamic aspects of vascular lesions. Increasingly,
ndothelial dysfunction has been recognized as important in
he pathophysiology of atherosclerosis. Flow-mediated va-
odilation (FMD) of the brachial artery has received great
ttention in this regard; nonetheless, the assessment of
MD still remains more of research than of general clinical
nterest, due in large part to technical challenges presented
y current ultrasound approaches or previous strain-gauge
enous impedance plethysmography methods. Dupuis et al.
69) reported a highly original and simple imaging method
hat appears to be measuring FMD in conjunction with a
outine that can be incorporated into a standard clinical
yocardial perfusion protocol. The researchers evaluated
he feasibility and validity of quantifying the hyperemic
esponse in the forearm after injection of a technetium-99m
etrofosmin, a radiopharmaceutical in widespread use for
PS. A standard dose of tetrofosmin was injected follow-
ng 5 min of right-arm ischemia. The forearms were then
maged using a standard nuclear medicine camera for 10
in, beginning 30 s after injection. The scintigraphic
yperemic reactivity was then assessed from the ratios of
arameters from the activity-time curves between the fore-
rms. In 46 patients with CAD compared to 47 patients
ithout evidence of CAD, the hyperemia ration predicted
he presence of CAD with a sensitivity of 70% and a
pecificity of 60%.
Differences on the order of 40% to 50% in the ratio of
aximal upslope between the arms were the most predictivef the presence of CAD. The clinical importance of this pnteresting approach will await validation that the method
orrelates well with traditional methods of assessing FMD
s well as further assessment as to whether this method
rovides significant incremental diagnostic, prognostic, or
anagement information over that provided by the associ-
ted MPS examination.
elayed enhancement. Cardiac magnetic resonance con-
inues to offer great promise in clinical cardiology. The area
n which this method has had the largest clinical impact is
n imaging of MI or scarring by gadolinium delayed
nhancement (DE). A large body of literature in animal and
uman studies has documented that this approach is highly
ensitive and specific for infarcted or scarred myocardium.
everal studies in JACC in 2004 have broadened our
nderstanding of the phenomenon of DE (70–73). Moon
t al. (70) used the assessment of DE to determine the
athological basis of Q-wave myocardial infarction
QWMI) and non–Q-wave myocardial infarction
NQWMI). The investigators studied 100 consecutive pa-
ients with pervious MI who had ECG and CMR on the
ame day; patients with acute MI within seven days were
xcluded. Size and transmural extent of MI were quantified
y DE CMR. Subendocardial and transmural components
ere common in both QWMI and NQWMI; fully 99% of
atients with QWMI had at least some of their infarct in a
ubendocardial distribution and 28% of patients with a
QWMI had regions of infarct that were transmural. As
he size and number of segments with transmural MI by DE
ncreased, the probability of Q waves increased; however,
he total size of MI by DE was the strongest predictor of Q
aves, and when it was considered, the transmural extent of
I was not an independent predictor. Although the divi-
ion into QWMI and NQWMI is useful because the former
redicts a larger MI, the findings of this study (70) show
hat the division into transmural and non-transmural MI is
ess meaningful.
AD
arkers. The search for more sensitive and earlier markers
n the diagnosis of AMI continued in 2004. Recognizing
he role of inflammation in unstable angina and MI, Patti et
l. (74) evaluated serum levels of the inflammatory mediator
nterleukin-1 receptor antagonist (IL-1RA) in 44 patients
ith MI. They found that IL-1RA levels were elevated
arlier in the course of MI than the commonly available
iomarkers such as myoglobin and troponin. The sensitivity
n patients presenting 3 h from onset of symptoms was
6% and was 91% in patients with heralded infarction.
B-type natriuretic peptide continued to be a focus of
ontinued intense investigation. Logeart et al. (75) studied
07 HF patients. The predischarge BNP assay had better
iscriminative power (area under the ROC curve  0.80)
han EF and other clinical parameters. The risk of death or
e-admission increased in stepwise fashion with increasing
redischarge BNP levels (p  0.0001).
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January 4, 2005:137–53 Highlights of the Year in JACC 2004In follow-up to an earlier report, Landesberg et al. (76)
rovide additional data regarding markers and non-cardiac
urgery. They demonstrated that troponin elevations are
ommon after such surgery, strongly associated with post-
perative ischemia, predicted by inducible ischemia on
reoperative thallium scanning, and, most importantly, are
educed by preoperative coronary revascularization.
nflammation. Inflammation continued to attract atten-
ion as a central pathophysiologic mechanism not only in
oronary disease but also in other CVDs such as aortic valve
isease. Chandra et al. (77) compared inflammatory markers
nd CAD in patients with and without aortic sclerosis in a
ohort of 415 patients being evaluated for acute chest pain.
ortic sclerosis was present in 49% of these 415 patients, a
igher prevalence than seen in population-based studies,
ost likely due to the selection of patients with cardiac
ymptoms. There was an increased rate of cardiovascular
vents, defined as cardiovascular death or CAD, at one year
n those with aortic sclerosis (16.8% vs. 7.1%, p  0.002).
owever, in multivariate analysis aortic sclerosis was no
onger a significant risk factor, whereas CAD, advanced age,
F, and C-reactive protein (CRP) levels remained signifi-
ant. The investigators concluded that the increased inci-
ence of adverse cardiovascular events in patients with aortic
clerosis is associated with CAD and inflammation, not a
esult of the effects of valvular heart disease per se.
Inflammation also appears to play an important role in
dvanced aortic stenosis. In an immunohistological study on
alves excised at surgery, Mazzone et al. (78), found that
dvanced “degenerative” aortic valve stenosis appears to be a
hronic inflammatory process associated with atheroscle-
otic risk factors. The researchers detected the coexistence of
eoangiogenesis, T-lymphocyte infiltration, adhesion mol-
cules, and hsp60 gene expression. These inflammatory
ndings were absent in a control group of valves excised
wing to diseases of the proximal aorta.
Although most studies have focused on inflammatory
ediators and markers, there is also increased awareness
hat as in most biological systems there are both pro-
nflammatory and anti-inflammatory processes in play. A
articularly interesting anti-inflammatory mediator is IL-
0. Fichtlscherer et al. (79) studied endothelial function in
5 male patients with CAD. They not only found that
L-10 levels correlated positively with endothelial function,
ut also that even in the presence of elevated CRP levels
ndothelial function was preserved. This “ying-yang” (80)
oints to a balance of inflammation and anti-inflammation
n the body.
Anti-inflammatory effects may also be mediated by di-
tary intervention. The Mediterranean diet has been shown
o reduce cardiovascular risk, but the mechanisms underly-
ng this effect has not been fully elucidated. In a study from
reece (81) with over 3,000 participants, those in the
ighest tertile of adherence to a Mediterranean diet had, on
verage, 20% lower CRP levels (p 0.015), 17% lower IL-6
evels (p  0.025), 15% lower homocysteine levels (p  m.031), 14% lower white blood cell counts (p  0.001), and
% lower fibrinogen levels (p  0.025), as compared with
hose in the lowest tertile.
latelet/aspirin resistance. The role of platelets in inflam-
ation has emerged as an important aspect of atherothrom-
osis. One of the platelet-derived mediators of inflamma-
ion is the CD40-ligand (CD40L), with platelets being the
ain source of its soluble form. Understanding the mech-
nisms underlying soluble CD40L release from platelets was
ided through a study by Furman et al. (82). They demon-
trated that, whereas translocation of CD40L to the cell
embrane is not dependent on GP IIb/IIIa, its release is
ediated through GP IIb/IIIa and inhibited by the GP
Ib/IIIa receptor antagonists abciximab, eptifibatide, and
irofiban.
Resistance to antiplatelet agents (both aspirin and clopi-
ogrel) emerged as an important area of investigation.
ulcinelli et al. (83) prospectively studied 150 patients on
spirin as well as 80 patients prescribed ticlopidine. Platelet
unction was periodically monitored before and after 2, 6,
2, and 24 months. Aspirin demonstrated an antiplatelet
ffect at two months, Thereafter, however, this inhibitory
ffect progressively decreased. At 24-month follow-up,
ollagen-induced platelet aggregation was significantly
igher than that observed at 2 months (p  0.05). Con-
ersely, the inhibition induced by ticlopidine was constant
hroughout follow-up. Thus, long-term aspirin therapy was
hown to be associated with tachyphylaxis.
Does clopidogrel treatment eliminate the problem of
spirin resistance? At least in patients undergoing elective
CI the answer appears to be no. Chen et al. (84) used the
ltegra Rapid Platelet Function Assay-ASA to determine
spirin responsiveness of 151 patients scheduled for non-
rgent PCI. All patients received a 300-mg loading dose of
lopidogrel 12 h before and a 75-mg maintenance dose in
he morning of the PCI. Twenty-nine (19.2%) patients
ere found to be aspirin-resistant, with a significantly
igher incidence of females in the aspirin-resistant versus
spirin-sensitive groups. The incidence of any creatine
inase-myocardial band (CK-MB) elevation was 51.7% in
spirin-resistant patients and 24.6% in aspirin-sensitive
atients (p  0.006). Thus, despite pretreatment with
lopidogrel, patients with aspirin resistance as measured by
point-of-care assay demonstrated an increased risk of
yonecrosis following non-urgent PCI.
The search for a better aspirin was highlighted in a study
n the innovative compound NCX-4016 by Fiorucci et al.
85) in 46 volunteers. The NCX-4016 is an aspirin deriv-
tive containing a nitric oxide-releasing moiety that blocks
latelet activation and modulates tissue factor (TF) expres-
ion and cytokine release from lipopolysaccharide (LPS)-
timulated monocytes. The investigators demonstrate less
astric damage, equal platelet inhibition, while preventing
onocyte activation.
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Highlights of the Year in JACC 2004 January 4, 2005:137–53etabolic syndrome/obesity and overweight/dyslipidemia.
iven the pandemic and cardiac implications of obesity and
eing overweight, it is not surprising that many studies
ddressed this vital issue.
The importance of the metabolic syndrome in cardiac
isease was underscored by an analysis of a prospective study
f 1,742 hypertensive subjects by Schillaci et al. (86). Event
ates in the groups with one to five characteristics of the
etabolic syndrome were 1.54, 1.96, 2.97, 3.35, and 5.27
er 100 patient-years, respectively (p  0.001). A total of
93 patients (34%) had the metabolic syndrome. Patients
ith the syndrome had an almost double cardiovascular
vent rate than did those without (3.23 vs. 1.76 per 100
atient-years, p  0.001).
On a basic level it has been recognized that adipose tissue,
nce thought to be an inert organ that simply stored fat, is
n important regulator of metabolism and inflammation,
hrough the secretion of various cytokines, including leptin
nd adiponectin. The latter is believed to have anti-diabetic
nd anti-atherosclerotic effects. In a report by Ohashi et al.
87), the genetics of adiponectin and its effects on coronary
isease were explored. The investigators demonstrated that
he I164T polymorphism for the adiponectin gene was
ssociated with low adiponectin levels, the metabolic syn-
rome, and CAD. As for leptin, Wolk et al. (88) demon-
trated in a study of 361 patients with angiographic coro-
ary disease that leptin levels predicted future cardiovascular
vents, independent of lipid levels and CRP.
Although low-density lipoprotein (LDL) cholesterol is
ecognized as a key risk factor for atherosclerosis, the role of
ther lipid particles has also received rightful attention. Two
tudies addressed the role of remnant lipoproteins (RLP) in
therosclerosis. Fukushima et al. (89) demonstrated that
atients with CAD had higher RLP levels than patients
ithout CAD. Moreover, Kaplan-Meier analysis demon-
trated that higher RLP cholesterol levels in patients with
AD resulted in a significantly higher probability for the
evelopment of coronary events. An accompanying study by
posito et al. (90) addressed some of the underlying mech-
nisms in remnant metabolism. They followed 63 CAD
atients in whom kinetic studies of the in vivo catabolism of
hylomicron-like emulsions were performed with compari-
on to a control population. At enrollment into the study,
asting patients were injected intravenously with a
hylomicron-like emulsion labeled with radioactive triglyc-
ride (3H-TG) and cholesteryl esters (14C-CE) to evaluate
he efficacy of intravascular triglyceride (TG) lipolysis. The
AD patients demonstrated impaired intravascular TG
ipolysis and this impairment correlated with adverse clinical
vents in the CAD group.
ging. Why do elderly patients with MI have a worse
rognosis? The role of collaterals was assessed by Kurotobi
t al. (91) in 1,934 patients undergoing coronary angiogra-
hy within 72 h of their AMI using the Rentrop score. The
nvestigators found that the prevalence of collaterals de-
reased with age. Multivariate analysis showed that the ibsence of collaterals was an independent predictor of
n-hospital mortality in elderly patients70 years, although
his finding was not significant in patients 70 years.
linical trials and therapeutics. With the ageing of the
opulation the issue of stroke and attempts at reducing its
evastating effects have gained urgency. Papdemetriou et al.
92), in a predefined subgroup analysis of 1,518 elderly
atients (age 70 to 89 years) with isolated systolic hyper-
ension in the Study on Cognition and Prognosis in the
lderly (SCOPE) trial demonstrated an impressive 42%
eduction in stroke with the angiotensin receptor blocker
andesartan in comparison with other antihypertensive
reatment, despite little difference in blood pressure reduc-
ion. This finding confirms the benefit seen in a broader
opulation in the Losartan Intervention For Endpoint
eduction in hypertension (LIFE) study.
The role of sildenafil, a phosphodiesterase inhibitor, in
reatment of primary pulmonary hypertension was studied
n a cross-over blinded study in 22 patients. Exercise time
ncreased by 44% from 475  168 s at the end of placebo
hase to 686  224 s at the end of the sildenafil phase (p 
.0001). With sildenafil, cardiac index improved from 2.80
0.9 l/m2 to 3.45  1.1 l/m2 (p  0.0001), whereas
ulmonary artery systolic pressure decreased insignificantly
rom 105.23  17.82 mm Hg to 98.50  24.38 mm Hg.
Despite their acceptance in guidelines as an important
herapy in ST-segment elevation MI, the use of beta-
lockers in primary PCI has not been studied in a random-
zed clinical trial, with clinical use based on extrapolation
rom pre-lytic and lytic trials. Three studies addressed this
mportant issue in a retrospective manner. Mehta et al. (93)
resented data from 3,065 patients in the PAMI trials. Lack
f preprocedural beta-blocker use was found to be a risk
actor for ventricular tachycardia (VT)/ ventricular fibrilla-
ion (VF) during primary PCI (odds ratio [OR] 2.34, 95%
onfidence interval [CI] 1.35 to 4.07). Similarly, data was
resented by Nikolsky et al. (94) from the Controlled
bciximab and Device Investigation to Lower Late Angio-
lasty Complications (CADILLAC) trial. A total of 1,136
atients (54.5%, BB group) received beta-blockers before
CI, whereas 946 (45.5%, BB group) did not. The 30-day
ortality was significantly lower in the BB group than in
he BB group (1.5% vs. 2.8%, p  0.03), an effect entirely
imited to patients who had not been receiving beta-blockers
efore admission (1.2% vs. 2.9%, p 0.007). In contrast, no
urvival benefit with pre-procedural beta-blockers was de-
ected in patients receiving beta-blockers at home (3.3% vs.
.9%, respectively, p  0.47). The use of post procedure
eta-blockers was assessed by Kernis et al. (95) in 2,442
atients in the PAMI trials. They found that at six months,
atients receiving beta-blockers were less likely to die (2.2%
s. 6.6%, p  0.0001) or experience MACE (14% vs. 17%,
 0.036). In multivariate analysis, beta-blockers werendependently associated with lower six-month mortality.
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blation of atrial fibrillation (AF). Recent studies have
hown that areas of complex fractionated atrial electrograms
CFAEs) correlate with areas of slowed conduction and
ivot points of reentrant wavelets that may perpetuate AF.
ademanee et al. (96) hypothesized that such areas of
FAEs could be identified and ablated, thus curing AF.
he researchers, therefore, studied 121 patients, mean age
3 years, with refractory AF, 57 of whom had paroxysmal
nd 64 of whom had chronic AF. The investigators per-
ormed nonfluoroscopic electroanatomic mapping of both
tria. CFAEs identified in these defined regions during AF
ere then ablated using radiofrequency (RF) energy until
F terminated or all areas with CFAEs were ablated.
FAEs were found in seven out of nine regions of both
tria. Ablations of areas associated with CFAEs resulted in
ermination of AF without external cardioversion in 115 of
21 patients, although 32 required adjunctive therapy with
butilide. A one-year total of 110 patients were free of AF
nd arrhythmia-related symptoms. The investigators con-
luded that atrial areas with CFAEs represent a defined
lectrophysiologic substrate and are ideal target sites for
blation to eliminate AF.
Chen et al. (97) determined the safety and efficacy of
ulmonary vein isolation (PVI) using RF catheter ablation
o treat AF in patients with impaired LV systolic function.
reviously published data on PVI for treatment of AF has
een limited to patients with normal LV function. The
nvestigators retrospectively evaluated 94 patients with LV
F40%, among 377 consecutive patients undergoing PVI
etween December 2000 and January 2003 at their institu-
ion. End points included AF recurrence, changes in LV EF
nd quality of life scores (QoL). After initial PVI, 73% of
atients with reduced LV EF compared to 87% of patients
ith normal LV EF were free of AF recurrence at 14  6
onths (p 0.03). In the study group, there was a small but
tatistically insignificant increase in EF of 4.6%, but a
ignificant improvement in QoL. Complication rates were
ow and were not different between groups. Although the
ecurrence rate of AF after initial PVI in patients with
educed LV EF was higher than with normal LVEF, nearly
hree-fourths of patients with reduced LV EF remained free
f AF during follow-up. The investigators suggest that PVI
ay be feasible in AF patients with reduced LV EF.
It is uncertain whether men and women differ in fre-
uency of arrhythmia recurrence, and whether any observed
ender differences are independent of clinical, ECG, and
lectrophysiologic (EP) characteristics (98). Lampert et al.
98) analyzed the clinical records and implantable
ardioverter-defibrillators (ICDs) data disks of 340 men and
9 women with CAD who received an ICD capable of
toring multiple arrhythmia episodes in memory. During an
verage follow-up of 30  22 months, the investigators
bserved that sustained VT/VF occurred in 52% of men and
4% of women (p  0.01), and that men experienced more Dotal VT/VF events (p 0.01), more shock-treated VT/VF
vents (p  0.03), more episodes of electrical storm (p 
.001), and had VT/VF on more days in follow-up (p 
.01) compared to women. The observed gender differences
ere independent of all other clinical, ECG, and EP
ariables analyzed. Gender differences in VT/VF recurrence
ere greatest in patients with sustained monomorphic VT,
nd those with inducible VT at EP study. The researchers
oncluded that among the CAD patients with ICDs,
omen were significantly less likely to experience VT/VF,
nd had fewer VT/VF episodes, than men.
ause of death in Multicenter Automatic Defibrillator
mplantation Trial (MADIT)-II. Greenberg et al. (99)
ought to identify the cause of sudden and presumably
rrhythmic death versus non-sudden cardiac death, in the
ADIT-II. To better understand the modes of death
ight lead to more rational and effective therapeutic inter-
entions in such high-risk populations. The MADIT-II
rial involved a 31% mortality decrease in 1,232 post MI
atients and low EF (30%) randomized to ICD implan-
ation versus conventional medical therapy. A total of 202
eaths were evaluated, using a variation of the Hinkle-
haler classification system as well as a clinical classification
ystem. The sudden cardiac death rates were 10.0% in the
onventional group and 3.8% in the ICD group (p  0.01),
ith a hazard ratio for sudden cardiac death risk in the
efibrillator group of 0.33 (95% CI 0.20 to 0.53; p 
.0001). Sudden cardiac death made up 51% and 61% of the
otal and cardiac deaths, respectively, in the conventional
herapy group compared with 27% and 35% in the ICD
roup. However, the ICD had no significant effect on
on-sudden death. Thus, the data indicate that the decrease
n mortality with ICD therapy in the MADIT-II is entirely
ue to a reduction in sudden cardiac death. However, lethal
rrhythmias were confirmed as the cause of sudden cardiac
eath in the majority of cases. In future ICD trials the
linical classification of cardiac death should be integrated
ith the terminal rhythm from postmortem ICD interro-
ation to help identify patients who will not benefit from
CD therapy.
CDs. Although the correct approach to management of
symptomatic patients with Brugada syndrome and induc-
ble ventricular arrhythmias remains controversial, class Ia
ntiarrhythmic drugs, which inhibit the transient outward
urrent (Ito) of the action potential, have been proposed as
ffective treatment. From a cohort of 106 patients with
rugada syndrome, Hermida et al. (100) studied 35 patients
ho received hydroquinidine. Patients had either asymp-
omatic Brugada syndrome with inducible arrhythmia
n31) or were symptomatic with multiple ICD shocks. A
slow release” hydroquinidine was given 300 mg twice a day
nd was increased to 900 mg /day if patients were still
nducible and had a plasma level 3 mol/l. Hydroquini-
ine was observed to prevent VT/VF inducibility in 76% of
symptomatic patients who underwent EP-guided therapy.
uring 17  13 months of follow-up, syncope occurred in
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Highlights of the Year in JACC 2004 January 4, 2005:137–53of the 21 patients on hydroquinidine therapy. In asymp-
omatic ICD patients (n  10), one patient received an
ppropriate shock during 13  8 months of follow-up. In
ymptomatic patients with multiple ICD shocks, hydro-
uinidine prevented VT/VF recurrence in all cases during a
ean follow-up of 14  8 months. Thus, hydroquinidine
herapy prevented VT/VF inducibility in the majority of
symptomatic patients with Brugada syndrome and VT/VF
ecurrence in all patients with multiple ICD shocks. The
nvestigators suggest that treatment with hydroquinidine
ay be an alternative to ICD as primary preventative
herapy in asymptomatic patients with Brugada syndrome
nd inducible arrhythmia. However, as the researchers note
n their report, this study was not randomized or controlled,
he number of patients was small and the follow-up dura-
ion short, and there was no ECG documentation of the
ause of the clinical events in patients taking
ydroquinidine.
It is uncertain whether AF is abolished by eliminating the
nitiating triggers by electrically isolating the pulmonary
eins, or by preventing perpetuation of AF by altering left
trial EP substrate. It is also not known whether circular
lus linear left atrial ablation produces an “all or none”
esponse or modifies the number and duration of AF
pisodes. Kottkamp et al. (101) analyzed the duration of AF
pisodes before and after circular plus linear left atrial
blation, and the percentage of patients with complete
reedom from AF after ablation, by comparing 24-h with
-day ambulatory ECG monitoring. In 100 patients with
aroxysmal (n  80) or persistent (n  20) AF, the relative
eriod spent in AF decreased significantly over time from an
verage of 35% before ablation, to 26% immediately after
blation, to 10% after 12 months. Freedom from AF
radually increased in patients with paroxysmal AF after 12
onths to 88% or 74% by 24-h or 7-day ECG monitoring.
he investigators demonstrated complete pulmonary vein
solation (PVR) in 20% of subjects. The researchers
oncluded that circular plus linear left atrial ablation for the
reatment of AF produced substrate modification as the
ain salutary mechanism and that this approach results in a
elayed as opposed to immediate cure. The data also suggest
hat the use of longer duration monitoring produces a more
ccurate assessment of cure rates of ablation for AF.
To examine whether ICD utilization in survivors of
ardiac arrest (CA) is adequate, Saba et al. (102) analyzed
he incidence of ICD therapy in survivors of CA in the U.S.
rom 1996 through 2001. The National Hospital Discharge
urvey (NHDS) was used to obtain data. The investigators
earched for patients admitted with the primary diagnosis of
A who survived to hospital discharge. Patients with a
oncomitant diagnosis of AMI or prior ICD in situ were
xcluded. Of 49,517 patients who survived CA, 30.7%
eceived an ICD before discharge, with a gradual increase in
mplantation rates from 1996 (23.6%) to 2001 (46.3%).
sing logistic regression for the years 2000 and 2001, Sabat al. (102) determined that patients who were discharged tithout an ICD were older, more likely to be of African-
merican race, and more likely to be admitted to a smaller
ospital. These predictors were independent of other co-
orbid illnesses. The authors concluded that, although
radually increasing during the period of study, rates of ICD
mplantations after CA still remain low, and that there are
ifferences in implantation rates by race.
ONGENITAL HEART DISEASE
uctus arteriosus. A controlled stenting of the ductus-
rteriosus will provide a systemic to pulmonary shunt for
abies with right-sided outflow obstruction and could pro-
ide a guaranteed systemic circulation for babies with left
eart atresia or hypoplasia. The ductus is a dynamic struc-
ure, and opening it with a stent has caused complications
uch as constriction and/or ductal laceration. In a multi-
enter study, investigators from Leuven and Toronto re-
orted a combined experience using 4-F, outer diameter
oronary stents, 13 to 24 mm positioned within the duct
103). In 10 patients with ductal dependent pulmonary
rtery circulation, 13 stents were implanted with a mean
uoroscopy time of 9 to 58 min. There was adequate growth
f the pulmonary arteries and gradual lumen narrowing of
he ductus lumen through intimal hypoplasia. All of the
atients later went on to the next stage of surgery. These
ong flexible stents appeared quite effective, but like coro-
ary stents they were subject to neo-intimal proliferation.
ostoperative patients with tetralogy of Fallot are at risk of
unctional deterioration in the face of significant added RV
ork if they have significant pulmonary insufficiency.
ulmonary artery stents. Younes Boudjemline, in con-
unction with Phillip Bonhoeffer, a pioneer of percutaneous
alve development, report a self-expandable valve stent that
an be deployed in a dilated RV outflow tract (104). The
0-mm diameter stent contains a bovine jugular vein valve
ounted in an hour-glass constriction that provides a
ulmonary valve annulus. One-step procedures put the valve
irectly in place while two-step procedures placed an outer
tent and then the inner stent containing the valve. Eight of
he ten devices were successfully delivered in ewes. Step-
ise reduction in the pulmonary artery size was achieved
s was valve implantation. Of the stents placed, there were
o early or late migrations and no significant gradient. One
roup was studied immediately after implant and the other
roup was studied two months’ post-implantation.
A study from the University of Chicago and Columbia
niversity in New York by Pass et al. (105) reviews a
5-center experience of 484 patients from September 1999
o June 2002 who underwent ductal occlusion with the
mplatzer device. Of the 484 patients with ductus enrolled,
o implantation was attempted in 45 patients. Implantation
as successful in 435 of the 439 patients attempted, 329 of
hich resulted in complete closure. The patients’ ages
anged from a little over 2 months to 70 years. Follow up of
he 49 patients with residual shunts at 24 h showed 41 of 43
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onths. This large study demonstrated that the widely used
mplatzer device, can effectively close moderate to large
uctal shunts with excellent one year results.
icuspid aortic valve. A study from Ospedale Pediatrico
ambino Gesu and Boston Children’s Hospital (106) re-
orts an 11-year follow up of 1,135 pediatric patients 18
ears of age diagnosed with bicuspid aortic valve from 1986
nd 1999. The study relates aortic valve morphology and
ong-term status determined between 5 and 19 years after
iagnosis. The vast majority of patients had right and left
oronary leaflet fusion resulting in a horizontal aortic valve
aphe, and this was also the most common form in those
ho had coarctation. Fusion of the right coronary and
on-coronary leaflets with a vertical appearing commissure
as associated with greater odds for both more significant
radient and/or more significant aortic regurgitation on
chocardiogram at follow up. The study demonstrates that
he risk factors for progression of isolated aortic valve
isease are not the same for all bicuspid aortic valves.
ortic complications of coarctation. Oliver et al. (107)
tudied 235 patients treated for coarctation treated either
urgery or balloon angioplasty. Surgery was performed in
81 patients, balloon angioplasty without stenting in 28 and
6 patients were untreated. The investigators looked at
ther complications related to the aorta. There were 44
ortic wall complications resulting in death or the need for
urgical intervention including ascending or descending
ortic aneurysms, aortic rupture, false aneurysms, aortic
issection, or fistula. They examined quality of repair and
ype of repair as well as morphology of the aorta in their
tudy. The complications of ascending or descending aneu-
ysms were not specifically associated with the time or type
f coarctation treatment. Thirty-seven of the patients had
hese serious complications; about 16% had false aneurysm,
upture, and dissection. The risk complications increased
ith age and was independently related to the diagnosis of
icuspid aortic valve. The study emphasizes that coarctation
atients, even with good results, need ongoing surveillance
ecause they have abnormal aortic structure. The abnormal
orta is stiff in these patients and pulse wave propagation is
ncreased. The abnormal aortic structure makes them at risk
or these types of complications. Recently, follow-up guide-
ines for coarctation in adults have emphasized the abnormal
rchitecture of the aortic wall in coarctation and the needs
or ongoing evaluation of patients.
trial septal defect (ASD) closure devices. A study by
rumsdorf et al. (108) from Frankfurt, reports the incidence
nd clinical course of thrombus formation on ASD or
atent foramen ovale (PFO) closure devices in 1,000 con-
ecutive patients who had PFO, 593 of who were ASD.
atients underwent closure with a variety of devices. All the
atients had TEE after four weeks and six months with
dditional TEEs as clinically indicated. Patients received
outine aspirin and clopidogrel. The incidence of thrombus
ormation was 7.1% on the Cardioseal, 5.7% on the Starflex device, 6.6% on the PFO star, and 0% on the Amplatzer
evice. Twenty-eight patients had thrombus formation on
heir device; in 17 of 20, the thrombus resolved under
nticoagulation; in three patients the thrombus was re-
oved surgically. Thrombus was most common on the left
ide of the device and occurred in 1.2% of ASD patients and
.5% in PFO patients. Post-procedural AF and persistent
trial-septal aneurysm were significant predictors of throm-
us formation. One patient had the Starflex device removed
ogether with thrombus after suffering a stroke. Post-
rocedural shunt occurred in 15% of the patients with
hrombus (3 of the 20), as did wire fracture on the right side
f the septum.
RECLINICAL STUDIES
se of granulocyte macrophage-collagen stimulating fac-
or (GM-CSF). Inflammatory responses after AMI affect
V remodeling. Maekawa et al. (45) examined the role of
acrophages and monocytes by treating rats with ro-
urtide, an inducer of GM-CSF, for one week after MI.
reatment increased circulating monocytosis and macro-
hage infiltration into the infarct, with adverse effects on
emodeling, infarct expansion, decreased LV function, and
ncreased mortality. These results have implications for the
ecent use of granulocyte and GM-CSF to mobilize endo-
helial progenitor cells, as discussed in an editorial comment
46). Stem cells may be harvested for injection into the
nfarct region to decrease infarct size, remodeling, and
ortality. However, the simultaneous mobilization of
onocytes and macrophages early after AMI may have the
ndesirable effects of exacerbating remodeling and
ortality.
poptosis. Apoptosis is associated with MI and HF.
owever, it is unknown whether inhibiting apoptosis affects
entricular remodeling and/or alters the development of
F. Chandrashekhar et al. (47) examined these issues by
nhibiting caspase, a key step in the apoptosis pathway, for
our weeks following MI in rats. The inhibitor decreased
aspase-3 activity, decreased cardiac apoptosis, and attenu-
ted the decline in LV function and remodeling. Regulating
poptosis may be a novel therapeutic target to attenuate
entricular remodeling and improve ventricular function
fter an MI.
ostconditioning. Timely reperfusion is crucial for salvag-
ng myocardium in AMI. The method of reperfusion also
ay affect the outcome. Yang et al. (48) used a rabbit infarct
odel to demonstrate that four 30-s cycles of reperfusion
nterrupted by reocclusion significantly decreased infarct
ize from 35% to 20% of the risk zone. This confirms the
xistence of a recently described phenomenon termed isch-
mic postconditioning, which has been demonstrated in
ifferent species. This has practical implications as the
ardioprotective effects are elicited after ischemia has been
stablished, whereas in the better-known ischemic precon-
itioning, beneficial effects are linked to events that occur
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omment (49), postconditioning may involve both similar
e.g., KATP-channel) and different signaling pathways as
schemic preconditioning. Staged, controlled reperfusion
trategies may provide additional benefits to improve out-
omes with reperfusion.
ibernation. Contractile and metabolic function in hiber-
ating myocardium improves with the restoration of myo-
ardial blood flow. Elsasser et al. (50) examined whether cell
eath occurs in chronic hibernating myocardium. Hibernat-
ng myocardium was documented in patients undergoing
evascularization. Systematic analyses of tissue demon-
trated increased cell death from apoptosis and autophagic
ell death involving ubiquitin. The presence of multiple
echanisms for myocyte degeneration and cell death in
hronic hibernating myocardium indicates that delays in
estoring myocardial blood flow may allow irreversible cell
eath to limit the extent of functional recovery.
yocardial regeneration. Stem cells and progenitor cells
rom different sources have been used to repair damaged
yocardium after infarction, but there are scant data eval-
ating outcomes based on face to face comparisons. Agbulut
t al. (51) found that transplantation of human skeletal
yoblasts and bone marrow derived CD133 progenitor
ells had comparable effects in improving LV function and
nducing angiogenesis after infarction in mice. The equiv-
lency in results despite differences in engraftment suggests
ifferences in mechanisms. These results have important
mplications, as discussed by Dimmeler and Zeiher in their
ditorial comment (52). Cell types differ in their capacity to
ifferentiate, engraft, secrete mediators, modify healing
rocesses, and induce complications (e.g., arrhythmias). As
lternative sources and clinical applications of stem and
rogenitor cells are sought, it will be a challenge to identify
he best cells for cardiac regeneration and vascularization
ntil the mechanisms for benefits are better understood and
rucial safety issues are addressed.
yocarditis. A study by Nishii et al. (53) demonstrated
hat serum interleukin (IL)-10 levels at the time of admis-
ion in patients with documented fulminant myocarditis are
redictive of which patients are likely to need LV assist
evice implantation or go on to die from their disease. This
s especially important in patients with fulminant myocar-
itis as there is a good chance of a favorable clinical outcome
f the patients are supported through the severe hemody-
amic compromise that accompanies their presentation.
urthermore, it demonstrates the potential value of serum
iomarkers in myocarditis because similar findings did not
ccur in patients requiring hemodynamic support during
I. Although this study was performed on a relatively small
umber of patients, it was interesting that there was a cutoff
alue above which serum IL-10 levels predicted the likeli-
ood of need for implantation of mechanical assist devices.
he implications of this study were commented on in an
ccompanying editorial (54).
It has been previously demonstrated in genetic and viralorms of cardiomyopathy that alterations in the dystrophin
lycoprotein complex can contribute to the pathogenesis of
ilated cardiomyopathy. In a report by Vatta et al. (55), it
as shown that disruption of the amino terminus of
ystrophin can occur in patients with cardiomyopathy of
schemic or unknown etiologies. In addition, the investiga-
ors demonstrated that dystrophin localization to the sarco-
emma is improved in both the LV and RV following
entricular assist device implantation. The improvement
ccurred with either pulsatile or continuous-flow ventricular
ssist devices. These findings suggest the possibility that
isruption of the dystrophin glycoprotein complex may play
role in a broad spectrum of cardiomyopathies and dem-
nstrate that improvement in this molecular phenotype in
oth ventricles occurs with implantation of a ventricular
ssist device.
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